Chemomab Therapeutics Ltd.

Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.

CMMB | NDAQ

Overview

Corporate Details

ISIN(s):: US16385C1045 (+1 more)
LEI:
Country:: United States of America
Address:: KIRYAT ATIDIM, BUILDING 7, 6158002 TEL AVIV
Website:: https://www.chemomab.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's approach is centered on its discovery of the soluble protein CCL24 as a key driver of the vicious cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class, dual-activity monoclonal antibody designed to bind to and neutralize CCL24. Nebokitug has demonstrated disease-modifying potential and a favorable safety profile in multiple clinical trials for severe fibrotic diseases. Following positive Phase 2 data, Chemomab is preparing for a potential Phase 3 trial in primary sclerosing cholangitis (PSC), for which nebokitug has received FDA Fast Track and Orphan Drug designations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Chemomab Therapeutics Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chemomab Therapeutics Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Chemomab Therapeutics Ltd. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Biosergen AB Developing novel antifungal drugs for life-threatening infections in immunocompromised patients.	Sweden	BIOSGN
Bio Solution Co.,Ltd. Develops cell therapies for degenerative diseases and supplies bio-lab reagents for R&D.	South Korea	086820
Biosynex European manufacturer of rapid diagnostic tests for professionals and consumer self-tests.	France	ALBIO
BIO-TECHNE Corp Develops reagents and instruments for life sciences research and clinical diagnostic markets.	United States of America	TECH
biote Corp. Trains practitioners in hormone optimization using bioidentical pellets and nutraceuticals.	United States of America	BTMD
Biotest AG Develops plasma protein products & biotherapeutics for immunology, haematology & intensive care.	Germany	BIO3
Biotika A.S. Biotech firm making penicillin & polymyxin B APIs for human/vet use, plus contract manufacturing.	Slovakia	BSL
Bioton S.A. Develops and manufactures recombinant human insulin for global diabetes care solutions.	Poland	BIO
BIOVENTIX PLC Develops high-affinity sheep monoclonal antibodies for global clinical diagnostic immunoassays.	United Kingdom	BVXP
Bioversys N Develops novel therapeutics to combat antimicrobial resistance in life-threatening infections.	Switzerland	BIOV